Tolerizing immune modifying nanoparticles for myasthenia gravis treatment
AssigneeCour Pharmaceuticals Development Company, Inc.
InventorsAdam Elhofy, Greta Wodarcyk, Michael Boyne
Life of this patent
Estimating the term…
Abstract
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Claims146
A composition comprising tolerizing immune modifying particle-Myasthenia Gravis (TIMP-MG) particles encapsulating one or more Myasthenia Gravis (MG) associated antigens, portions thereof, or combinations thereof.
A method of inducing tolerance in a subject in need thereof comprising administering to the subject a composition comprising negatively charged particles encapsulating an antigen, wherein the antigen is one or more Myasthenia Gravis (MG) associated antigens, portions thereof, or combinations thereof.
A method of treating Myasthenia Gravis (MG) in a subject comprising administering to the subject tolerizing immune modifying particles encapsulating one or more MG associated antigens (TIMP-MG).
A method for preparing a composition comprising particles encapsulating one or more MG associated antigens, the method comprising:
- (a) generating an aqueous solution of one or more MG associated antigens;
- (b) generating a primary emulsion by mixing an aqueous solution of step (a) with an oil phase including a polymer;
- (c) mixing the primary emulsion with a mixture comprising one or more surfactants and/or stabilizers to form a secondary emulsion;
- and
- (d) hardening the secondary emulsion of step (c) by evaporation resulting in hardened polymeric nanoparticles encapsulating MG associated antigens within their cores.
The method of any one of the preceding claims, wherein the manufacturing batch size is between 0.01 g to 100 kg.
A pharmaceutical composition comprising negatively charged particles encapsulating Myasthenia Gravis (MG)-associated antigens, sucrose, mannitol, and sodium citrate.
A composition comprising liposomes encapsulating one or more Myasthenia Gravis (MG) associated antigens, portions, or combinations thereof.
Dependencies are inferred from the claim text.